Histogenics Corp. closed an underwritten public offering to raise about $15.4 million in net proceeds.
The Waltham, Mass.-based company sold 26,155,000 common shares and accompanying warrants to buy up to 19,616,250 shares at a combined price of 65 cents apiece.
Histogenics previously stated that it plans to use the proceeds to fund the regulatory approvals and commercialization of its cartilage repair therapy platform called NeoCart and for general corporate purposes.
Canaccord Genuity LLC and BTIG LLC served as joint book-running managers, while H.C. Wainwright & Co. LLC acted as the co-manager for the offering. CIM Securities LLC acted as a financial adviser to Histogenics in connection with the offering.